EFAXAGLUTIDE ALFA
UNII UJ5FNG466G
Substance Identification & Data
This profile provides standardized clinical and technical data for Efaxaglutide Alfa, uniquely identified by the FDA Unique Ingredient Identifier (UNII) UJ5FNG466G.
Technical mappings include the Chemical Abstracts Service (CAS) Registry Number 3069923-11-8 and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.
UJ5FNG466G
3069923-11-8
N/A
Detailed Substance Profile
Preferred Name
EFAXAGLUTIDE ALFA
Official standardized name for this substance within the FDA UNII nomenclature system.
INN ID
14125
Sequential identifier assigned via the WHO International Nonproprietary Name program.
Substance Type
Efaxaglutide Alfa
ISO 11238 classification category (e.g., Chemical, Polymer, Protein).
Synonyms and Nomenclature
This section provides a complete list of nomenclature and identifier mappings for Efaxaglutide Alfa. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.
FDA Official Name
Efaxaglutide Alfa
Common Names & Synonyms
Glucagon-like peptide GLP-1 (7-35) [8-glycine] (human) fusion protein with extendin 4 (30-39) (synthetic) fusion protein with synthetic peptide linker ((GGGGS)6) fusion protein with glucagon-like peptide GLP-1-(7-35) [8-glycine] (human) fusion protein with extendin 4 (30-39) (synthetic) fusion protein with synthetic peptide linker ((GGGGS)3) fusion protein with immunoglobulin [33-glutamine,137-cysteine,149-tryptophan,211-leucine] (human hybrid γ1/δ-chain hinge-γ4-chain CH2-CH3 fragment), (134→59′)(137→62′)(260→180′)-tris-(disulfide) with glucagon-like peptide GLP-2 [2-glycine,16-glycine,17-glutamine] (human) fusion protein with synthetic peptide linker ((GGGGS)3) fusion protein with immunoglobulin [33-glutamine,132-cysteine,137-serine,151-alanine,190-valine,211-leucine] (human hybrid γ1/δ-chain hinge-γ4-chain CH2-CH3 fragment)
efaxaglutide alfa [INN]
human glucagon-like peptide 1 (GLP-1, Uniprot: P01275) (7-35, 1-29 in the current sequence), variant (A<sup>8</sup>>G<sup>2</sup>), fused at its C-terminus to an exendin 4 (Uniprot: P26349) peptide fragment (30-39) connected via peptide linker (G<sub>4</sub>S) <sub>6</sub> (40-69) to a second human glucagon-like peptide 1 (GLP-1, Uniprot: P01275) (7-35, 70-98 in the current sequence), variant (A<sup>8</sup>>G<sup>71</sup>) fused to an exendin 4 peptide fragment (99-108) connected via peptide linker (G<sub>4</sub>S) <sub>3</sub> (109-123) to a human immunoglobulin G4 (IgG4) Fc fragment (hinge-CH2-CH3-CHS domains) [Homo sapiens IGHG1*01 (hinge C<sup>128</sup>>S (124-138)), Homo sapiens IGHG4*01 (CH2 AP<sup>138-139</sup>>del, E<sup>139</sup>>S, F<sup>140</sup>>H, L<sup>141</sup>>T, G<sup>142</sup>>Q, G<sup>143</sup>>P, P<sup>144</sup>>L, S<sup>145</sup>>G, T<sup>156</sup>>Q (139-246), CH3 S<sup>260</sup>>C, T<sup>272</sup>>W, M<sup>334</sup>>L (247-351), CHS (352-353)) (124-353)], (134-59':137-62':260-180')-trisdisulfide with glucagon-like-2 (GLP-2, Uniprot: P01275) peptide (1'-33'), variant (H2'>G, N16'>G, L17'>Q), fused via peptide linker (G<sub>4</sub>S) <sub>3</sub> (34'-48') to a human immunoglobulin G4 (IgG4) Fc fragment (hinge-CH2-CH3-CHS domains) [Homo sapiens IGHG4*01 (hinge C<sup>53'</sup>>S (49'-63'), CH2 AP<sup>63'-64'</sup>>del, E<sup>64'</sup>>S, F<sup>65'</sup>>H, L<sup>66'</sup>>T, G<sup>67'</sup>>Q, G<sup>68'</sup>>P, P<sup>69'</sup>>L, S<sup>70'</sup>>G, T<sup>81'</sup>>Q (64'-171'), CH3 Y<sup>180'</sup>>C, T<sup>197'</sup>>S, L<sup>199'</sup>>A, Y<sup>238'</sup>>V, M<sup>259'</sup>>L (172'-276'), CHS (277'-278')) (49'-278'); produced in Chinese hamster ovary (CHO) cells, ZFN-engineered CHO-K1 GS-/- cell line, glycoform alfa
